Thursday, 15 October 2026European Markets

BEVER HOLDING Stock Over 18% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of BEVER HOLDING (AEX-Index: BEVER.AS) rose by a staggering 18.12% in 5 sessions from €2.76 to €3.26 at 05:09 EST on Wednesday, after two consecutive sessions in a row of losses. AEX-Index is sliding 0.97% to €756.67, after two consecutive sessions in a row of losses.

BEVER HOLDING's last close was €3.26, 24.19% under its 52-week high of €4.30.

About BEVER HOLDING

Bever Holding NV operates as a real estate company in the Netherlands and Belgium. It develops apartments, commercial spaces, and hotels. The company also invests in, acquires, and leases real estate properties. Bever Holding NV was incorporated in 1975 and is based in Wassenaar, the Netherlands.

Earnings Per Share

As for profitability, BEVER HOLDING has a trailing twelve months EPS of €-1.12.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -47.79%.

Moving Average

BEVER HOLDING's value is under its 50-day moving average of €3.58 and way under its 200-day moving average of €3.68.

Yearly Top and Bottom Value

BEVER HOLDING's stock is valued at €3.26 at 05:09 EST, way below its 52-week high of €4.30 and way above its 52-week low of €2.76.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.7%, now sitting on 1.05M for the twelve trailing months.

Volume

Today's last reported volume for BEVER HOLDING is 257 which is 115.96% above its average volume of 119.

More news about BEVER HOLDING (BEVER.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com